论文部分内容阅读
目的:分析阿司匹林联合阿托伐他汀对缺血性脑血管病患者血清氧化低密度脂蛋白(OxLDL)、超敏C反应蛋白(hs-CRP)水平的影响。方法:选取2014年4月至2015年4月在梅州市嘉应学院医学院附属医院治疗的缺血性脑血管患者106例,按抽签顺序分为两组,各53例。所有患者均进行常规治疗,对照组在此基础上采用阿司匹林治疗,观察组在对照组基础上加用阿托伐他汀治疗,对比两组患者治疗前后颈部动脉中膜厚度(IMT)、hs-CRP、OxLDL等指标的变化及不良反应情况。结果:治疗前,两组患者各项指标比较,差异均无统计学意义(P>0.05);治疗后,观察组IMT、hs-CRP、OxLDL水平较对照组明显降低,差异具有统计学意义(P<0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论:对缺血性脑血管病患者进行阿司匹林联合阿托伐他汀治疗,可有效改善患者IMT、hs-CRP、OxLDL水平,促进患者康复,且无明显不良反应,安全性较高。
Objective: To investigate the effects of aspirin combined with atorvastatin on the levels of serum oxidized low density lipoprotein (OxLDL) and high sensitivity C-reactive protein (hs-CRP) in patients with ischemic cerebrovascular disease. Methods: From April 2014 to April 2015, 106 cases of ischemic cerebrovascular patients treated at Jiaying College Medical College Affiliated Hospital of Meizhou City were selected and divided into two groups (n = 53) according to the order of lottery. All patients were treated routinely. The control group was treated with aspirin on this basis. The observation group was treated with atorvastatin on the basis of the control group. Before and after treatment, the mean arterial wall thickness (IMT), hs- CRP, OxLDL and other indicators of changes and adverse reactions. Results: Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, the levels of IMT, hs-CRP and OxLDL in the observation group were significantly lower than those in the control group (P < P <0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P> 0.05). Conclusion: Aspirin combined with atorvastatin in patients with ischemic cerebrovascular disease can effectively improve the level of IMT, hs-CRP and OxLDL in patients with ischemic cerebrovascular disease and promote the rehabilitation of patients with no obvious adverse reactions and high safety.